AU682238B2

AU682238B2 – Mutants of bone morphogenetic proteins
– Google Patents

AU682238B2 – Mutants of bone morphogenetic proteins
– Google Patents
Mutants of bone morphogenetic proteins

Download PDF
Info

Publication number
AU682238B2

AU682238B2
AU12093/95A
AU1209395A
AU682238B2
AU 682238 B2
AU682238 B2
AU 682238B2
AU 12093/95 A
AU12093/95 A
AU 12093/95A
AU 1209395 A
AU1209395 A
AU 1209395A
AU 682238 B2
AU682238 B2
AU 682238B2
Authority
AU
Australia
Prior art keywords
bmp
amino acid
ala
seq
val
Prior art date
1993-12-07
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Ceased

Application number
AU12093/95A
Other versions

AU1209395A
(en

Inventor
John Mccoy
Neil M Wolfman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Genetics Institute LLC

Original Assignee
Genetics Institute LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
1993-12-07
Filing date
1994-11-15
Publication date
1997-09-25

1994-11-15
Application filed by Genetics Institute LLC
filed
Critical
Genetics Institute LLC

1995-06-27
Publication of AU1209395A
publication
Critical
patent/AU1209395A/en

1997-09-25
Application granted
granted
Critical

1997-09-25
Publication of AU682238B2
publication
Critical
patent/AU682238B2/en

2003-02-06
Assigned to GENETICS INSTITUTE, LLC
reassignment
GENETICS INSTITUTE, LLC
Request to Amend Deed and Register
Assignors: GENETICS INSTITUTE INC.

2014-11-15
Anticipated expiration
legal-status
Critical

Status
Ceased
legal-status
Critical
Current

Links

Espacenet

Global Dossier

Discuss

Classifications

C—CHEMISTRY; METALLURGY

C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING

C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA

C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor

C12N15/09—Recombinant DNA-technology

C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity

C—CHEMISTRY; METALLURGY

C07—ORGANIC CHEMISTRY

C07K—PEPTIDES

C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof

C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans

C07K14/475—Growth factors; Growth regulators

C07K14/51—Bone morphogenetic factor; Osteogenins; Osteogenic factor; Bone-inducing factor

A—HUMAN NECESSITIES

A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE

A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

A61P19/00—Drugs for skeletal disorders

A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget’s disease

Abstract

DNA molecules encoding mutant forms of bone morphogenetic proteins (BMP) are disclosed, The mutant forms of BMP can be produced bacterially and refolded to produce biologically active homodimers or heterodimers of BMP. A method of making such mutant BMPs is also disclosed.

Description

A64 a 4 WO 95/16034 PCTIUS94113181 MUTANTS OF BONE MORPHOGENETIC PROTEINS The present invention relates to mutants of bone morphogenetic proteins.
These mutants are useful, particularly for use in improved processes for preparation of biologically active dimeric recombinant bone morphogenetic proteins produced in insoluble form from bacterial cell cultures.
BACKGROUND OF THE INVENTION A number of proteins referred to in the art as bone morphogenetic proteins (BMPs) have recently been identified which are able to induce bone or cartilage formation when implanted into mammals. For example, Wang et al. in U.S. patent 5,013,649, incorporated herein by reference, describe the DNA sequences encoding bovine and human bone morphogenetic proteins 2A (now bone morphogenetie protein-2) and 2B (now bone morphogenetic protein the corresponding proteins encoded by those DNA sequences, and processes for recombinant production of the BMP-2A (now BMP-2) and BMP-2B (now BMP-4) proteins. Wozney et al., in U.S.
5,106,748, incorporated herein by reference, describe the DNA and amino acid sequences of bovine and human bone morphogenetic protein-5 (BMP-5), along with processes for recombinant production of the BMP-5 proteins. In U.S. 5,187,076, incorporated herein by reference, Wozney et al. disclose DNA sequences, amino acid sequences, and process for recombinant production of human and bovine bone morphogenetic protein-6 (BMP-6), DNA and amino acid sequences encoding bone morphogenetic protein-7 (BMP-7, sometimes referred to as OP-1) and processes for recombinant production of BMP-7 are described in Rosen, et al., U.S. 5,141,905, incorporated nerein by reference. DNA sequences encoding BMP-8 are disclosed in PCT publication W091/18098. DNA sequences encoding BMP-9 are disclosed in PCT publication W093/00432. These references are herein incorporated by reference, These proteins are expected to have broad medical applicability in treatment of bone and cartilage injuries and disorders in mammals. In order to fulfill the expected medical need for these bone morphogenetic proteins, large quantities of biologically active protein will be needed.
I
116 ‘1 1* -7~Sn a WO 95/16034 PCT/US9413181 Recombinant production of the bone morphogenetic proteins is possible both in eukaryotic and prokaryotic cell culture systems. A common occurrence in recombinant production of heterologous protins in prokaryotic cells, such as bacteria, is the formation of insoluble intracellular precipitates known as inclusion bodies.
While the bacteria are generally able to transcribe and to translate DNA sequences encoding heterologous proteins correctly, these prokaryotic cells are unable to fold some heterologous proteins sufficiently correctly to allow for their production in a soluble form. This is particularly true of prokaryotic expression of proteins of eukaryotic origin, such as the bone morphogenetic proteins. Formation of incorrectly folded heterologous proteins has to some extent limited the commercial utility of bacterial fermentation to produce recombinant mammalian proteins. When produced in bacteria, the recombinant bone morphogeretic proteins are often similarly found in inclusion bodies in an aggregated, biologically inactive form.
Several methods for obtaining correctly folded heterologous proteins from bacterial inclusion bodies are known. These methods generally involve solubilizing the protein from the inclusion bodies, then denaturing the protein completely using a chaotropic agent. When cysteine residues are present in the primary amino acid sequence of the protein, it is often necessary to accomplish the refolding in an environment which allows correct formation of disulfide bonds (a redox system).
General methods of refolding are disclosed in Kolmo, Mpljh nzvn, 185:187-195 (1990).
EP 0433225 describes a method for refolding transforming growth factor 0 (TGF-1)-like proteins which employs, in addition to a chaotropic agent and a redox system, a solubilizing agent in the form of a detergent. EP 0433225 predicts that the methods disclosed therein are generally applicable for refolding «TGF-0-like proteins», based on the degree of homology between members of the TGF- family.
However, the present inventors have found that the methods disclosed in EP 0433225 produce undesirably low yields of correctly folded, biologically active dimeric protein when applied to bacterially produced BMP-4, BMP-5, BMP-6, or BMP-7 for unknown reasons.
-yynl~rrylr~ CMlg’~-W~Y*~y’l ~nyp~Sj~LL~i~TlSCI IU~il;lY~L~Url~~l-PFY~s/FI~*PIIIC~i~ql I II Y l r WO 95116034 PCTIUS94113181 SUMMARY OF THE INVENTION It has been found, unexpectedly, that although some bone morphogenetic proteins do not yield correctly folded, biologically active dimeric protein when produced bacterially, such as BMP-4, BMP-5, BMP-6, BMP-7, or BMP-8 certain mutant forms of these proteins are able to yield such proteins. It has further been found, also unexpectedly, that certain mutant forms of bone morphogenetic proteins are also able to yield correctly folded, biologically active heterodimers, such as heterodimers of BMP-2/5 and BMP-2/6, in good quantity, whereas the native forms of these proteins produce undesirably low yields of correctly folded, biologically active heterodimers, yields which are improved by the methods of this invention.
Accordingly, in one embodiment, the invention comprises mutant forms of BMP-4 which are useful in bacterial production processes for yielding correctly folded, biologically active forms of BMP-4.
In another embodiment, the invention comprises mutant forms of BMP-6, BMP-7 and BMP-8 which are useful in bacterial production processes for yielding correctly folded, biologically active forms of heterodimers of BMP-2/6, BMP-2/7 and BMP-2/8.
In a further embodiment, the invention comprises DNA molecules comprising DNA sequences encoding the above mutant forms of bone morphogenetic proteins.
The present invention further comprises a method for obtaining other mutants of bone morphogenetie proteins with improved refolding properties, and the mutant proteins thereby obtained.
SEQ ID NO:1 SEQ ID NO:2 SEQ ID NO:3 SEQ ID NO:4 SEQ ID NO:5 SEQ ID NO:6 SEQ ID NO:7 SEQ ID NO:8 SEQ ID NO:9 BRIEF DESCRIPTION OF THE SEQUENCES is the nucleotide sequence encoding BMP-2.
is the amino acid sequence for BMP-2.
is the nucleotide sequence encoding BMP-4.
is the amino acid sequence for BMP-4.
is the nucleotide sequence encoding is the amino acid sequence for is the nucleotide sequence encoding BMP-6.
is the amino acid sequence for BMP-6.
is the nucleotide sequence encoding BMP-7.
W095/16034 PCTIUS94/13181 SEQ ID NO:10 is the amino acid sequence for BMP-7.
SEQ ID NO:11 is the nucleotide sequence encoding BMP-8.
SEQ ID NO:12 is the amnno acid sequence for BMP-8.
DESCRIPTION OF THE FIGURE Figure 1 is a comparison of sequences of BMP-2, 4, 5, 6, 7 and 8.
DETAILED DESCRIPTION OF THE INVENTION In accordance with the present invention, mutant forms of recombinant bone morphogenetic protein-4 (BMP-4)(SEQ ID NO:3 and BMP-5 (SEQ ID NO:5 and BMP-6 (SEQ ID NO:7 and BMP-7 (SEQ ID NO:9 and 10); and BMP-8 (SEQ ID NO:11 and 12) may be used to produce large quantities of BMP homodimers or heterodimers from bacteria and refolded into biologically active dimeric molecules.
The DNA molecules of the present invention include DNA molecules comprising a nucleotide sequence encoding BMP-4, except that the nucleotide triplet encoding glutamic acid at residue 107 nucleotides 319 to 321 of SEQ ID NO:3) is replaced (for example, by mutation or synthetically) by a nucleotide triplet that encodes an aspartic acid at residue 107.
Another embodiment of the present invention comprises DNA molecules comprising a nucleotide sequence encoding BMP-5, BMP-6, or BMP-7, except that the nucleotide triplet encoding alanine at residue 56 of BMP-5 or BMP-6 nucleotides 166 to 168) of SEQ ID NO:5 or or residue 63 of BMP-7 nucleotides 187 to 189 of SEQ ID NO:9), is replaced (for example, by mutation or synthetically) by a nucleotide triplet that encodes a histidine.
Another embodiment of the present invention comprises DNA molecules comprising a nucleotide sequence encoding BMP-8, except that the nucleotide triplet encoding serine at residue 63 of BMP-8 nueleotides 187 to 189 of SEQ ID NO: 11), is replaced (for example, by mutation or synthetically) by a nucleotide triplet that encodes a histidine.
The present invention further comprises purified compositions of protein comprising the amino acid sequence of BMP-4, except that the amino acid WO 95/16034 PCTIJS94/13181 glutamic acid at residue 107 is replaced by an aspartic acid. This modified BMP-4 protein may be referred to by the nomenclature BMP4(AI07Asp).
In another embodiment, the present invention comprises purified compositions of protein comprising the amino acid sequences of BMP-5, BMP-6 or BMP-7, except that the amino acid alanine at residue 56 of BMP-5 or BMP-6, or residue 63 of BMP- 7, is replaced by a histidine. The modified BMP-5 protein may be referred to, for example, by the nomenclature BMP-5(A56His). in another embodiment, the present invention comprises purified compositions of protein comprising the amino acid sequences of BMP-8, except that the amino acid serine at residue 63 of BMP-8, is replaced by a histidine. The modified BMP-8 protein may be referred to, for example, by the nomenclature BMP-8(A63His).
As used herein, the term «correlative» means the following. It is known that BMP-2 comprises a dimer of polypeptide chains, each of which may be 114 amino acids in length. Similarly, BMP-4 comprises a dimer of polypeptide chains, each of which may be 116 amino acids in length. BMP-5 and BMP-6 each comprise dimers of polypeptide chains, each of which may be 132 amino acids in length. BMP-7 comprises a dimer of polypeptide chains, each of which may be 139 amino acids in length. BMP-8 comprises a dimer of polypeptide chains, cach of which may be 139 amino acids in length. It is further known that the amino acids of BMP-2 from the leucine at residue 19 (correlative to residue 21 of BMP-4) through arginine at residue 114 is highly homologous to BMP-4 from leucine at residue 21 to arginine at residue 116). Similarly, it is known that the amino acids of BMP-2 from leucine 19 of BMP- 2 through arginine 114 of BMP-2 are highly homologous to amino acids leucine 36 through histidine 132 of BMP-5 and BMP-6 and amino acids leucine 43 through histidine 139 of BMP-7, and to leucine 43 to histine 139 of BMP-8 Thus, the leucine at residue 19 of BMP-2 is said to be correlative to residue 21 of BMP-4, and to residues 36 of BMP-5 and BMP-6, and to residue 43 of BMP-7, and to residue 43 of BMP-8. Similarly, the aspartic acid at residue 105 of BMP-2 is said to be correlative to the glutamic acid at residue 107 of BMP-4, and the histidine at residue 39 of BMP-2 is said to be correlative to the alanine at residues 56 of BMP-5 and BMP-6 and the alanine at residue 63 of BMP-7, and the serine at residue 63 of BMP- WO 95116034 PCT/US9413181 8. Alternatively, the 112 amino acid sequence of TGF- may also be used as a reference point for defining correlative amino acids.
From an examination of Figure 1, it can be seen that BMP-2 and BMP-4 are highly homologous, beginning at the first cysteine (residue 14 of BMP-2; correlative residue 16 of BMP-4). There are only eight correlative residues which are different.
These are, respectively, at residues 15, 39, 46, 73, 95, 96 and 105 of BMP-2. Yet, Applicants have found that the methods disclosed in EP 0433225, which are effective for refolding BMP-2 in acceptable quantities, produce undesirably low yields of correctly folded, biologically active dimeric protein when applied to bacterially produced BMP-4. Applicants constructed molecules in which the first four (Nterminal) of these residues resembled the BMP-2 residue, while the last four (Cterminal) of these residues resembled the correlative BMP-4 residue (called «BMP- 2/BMP-4»). Applicants also constructed molecules in which the N-terminal four of these residues resembled BMP-4, while the C-terminal four of these residues resembled the correlative BMP-4 residue (called «BMP-4/BMP-2). As described in Example 2, Applicants found that while BMP-4/BMP-2 refolded in good quantity, BMP-2/BMP-4 did not.
The present invention includes DNA molecules comprising a DNA sequence encoding BMP-4, wherein at least the nucleotide sequence encoding the amino acid glutamic acid at residue 107 is replaced by the correlative nucleotide sequence of BMP-2 encoding aspartic acid. In addition, it is contemplated that other nucleotide sequences of BMP-4 may be replaced by the correlative nucleotide sequence of BMP- 2, so long as the glutamic acid residue at 107 is replaced by the correlative aspartic acid residue of BMP-2. Such a DNA molecule may be chimeric, that is, portions of BMP-2 coding sequence and BMP-4 coding sequence may be ligated together through methods readily known to those skilled in the art. Alternatively, this DNA molecule may be constructed synthetically or through mutations, such as by chemical means.
The DNA molecule, once formed can be dimerized through methods known in the art, either with itself (homodimer) or with a different member of the BMP family (heterodimer).
The present invention further includes DNA molecules comprising a DNA sequence encoding BMP-5, BMP-6, BMP-7, or BMP-8 wherein the nucleotide a~c WO 95/16034 PCT/US94/13181 sequence encoding the amino acid alanine at residue 56 of BMP-5 or BMP-6, or residue 63 of BMP-7 or BMP-8, is replaced by the correlative nucleotide sequence of BMP-2. In addition, it is contemplated that other nucleotide sequences of BMP-6, BMP-7 or BMP-8 may be replaced by the correlative nucleotide sequence of BMP-2, so long as the alanine residue at 56 (63 of BMP-7), or serine residue at 63 of BMP-8, is replaced by the correlative histidine residue of BMP-2. Such a DNA molecule may be chimeric, that is, portions of BMP-2 coding sequence and BMP-6, BMP-7 or BMP-8 coding sequence may be ligated together through methods readily known to those skilled in the art. Alternatively, this DNA molecule may be constructed synthetically or through mutations, such as by chemical means. The DNA molecule, once formed can be dimerized through methods known in the art.
The present invention further comprises methods of obtaining other mutants of bone morphogenetic proteins (BMP) with improved refolding properties, and the mutant proteins thereby obtained. The method comprises first comparing the amino acid sequence of a BMP which is found to refold well (BMP*) using the refolding methods described herein, with the amino acid sequence of a BMP which does not refold well using such methods (BMP), and the differences at correlative amino acid positions are determined. Next, the amino acid sequence of BMP is altered so that one or more aminos acids different from those of correlative amino acids of BMP* are replaced by the correlative amino acids of BMP*. For example, such modified amino acids could be formed by creating one or more nucleotide mutations or substitutions in the DNA sequence encoding the amino acid sequence for BMP so that the DNA sequence will express a modified BMP protein. The modified BMF protein is then tested for its ability to refold. This method may be repeated for each amino acid position at which the sequence of BMP* and BMP differ in order to identify those amino acid residues that are critical to the differences in refolding. Further, multiple changes to the amino acid sequence of BMP may be made to replace amino acid residues with the correlative amino acid from BMP* in order to further improve the refolding of the modified BAMP protein. The modified BMP’ proteins, and the DNA sequence encoding them, are also within the present invention.
Methods of mutagenesis of proteins and nuceleic acids are known, for example see Sambrook et al., Molecular Clnin-A Lahotortry Manual, 2d ed. (Cold Spring WO 95/16034 PCT/US94/13181 Harbor, Cold Spring Harbor Laboratory Press)(1990). It is further known that there may exist more than one nucleotide triplet that encodes a given amino acid residue. For example, a histidine residue may be encoded by either CAT or CAC, and an aspartic acid residue may be encoded by either GAT or GAC. See Lehninger, Biohemistry, (Worth Publishers, N.Y.) Any bacterial species may be used to generate recombinant BMP for refolding in the method of the invention. Pref:rably, Bacillus subtilis is used to produce inclusion bodies containing BMP. More preferably, Pseudomonas is used to produce inclusion bodies containing BMP for refolding in the method of the invention. Most preferably, Escherichia coli is used to produce inclusion bodies containing BMP for refolding in the method of the invention, Any strain of E. coli may be used to produce BMP for refolding in the method of the invention, so long as that strain is capable of expression of heterologous proteins. One preferred strain, E. coli strain GI724 accession number 55151) may be used to produce BMP for refolding in the method of the invention.
The mutant forms of BMP of the present invention may be produced in bacteria using known methods. It may be necessary to modify the N-terminal sequences of the mutant forms of BMP in order to optimize bacterial expression. For example, because cleavage of the bond between formyl-methionine and glutamine is inefficient in E. coli, the N-terminus of the native mature BMP-2 protein (Met-glnala-lys) is modified by deletion of the glutamine residue to yield an N-terminus more suitable for BMP-2 production in E. coli (Met-ala-lys-his). Other bacterial species may require analogous modifications to optimize the yield of the mutant BMP obtained therefrom. Such modifications are well within the level of ordinary skill in the art.
The modified or unmodified nucleotide sequence of SEQ ID NO:3 which encodes BMP-4; SEQ ID NO:5, which encodes BMP-5; SEQ ID NO:7, which encodes BMP-6; SEQ ID NO:9, which encodes BMP-7, or SEQ ID NO:11, which encodes BMP-8, may be inserted into a plasmid suitable for transformation and expression of those heterologous proteins in bacteria. Any bacterial expression plasmid may be used, so long as it is capable of directing the expression of a heterologous protein such as BMP in the bacteria chosen. Acceptable species of LI~ I- II WO 95/16034 PCT/US94/13181 bacteria include B. subtilis, species of Pseudomonas, and E. coli. Suitable expression plasmids for each of these species are known in the art. For production of BMP in bacteria, a suitable vector is described in Taniguchi et al., PNAS.:USA, 77:5230-5233 (1980).
The bacterial expression plasmid may be transformed into a competent bacterial cell using known methods. Transformants are selected for growth on medium containing an appropriate drug when drug resistance is used as the selective pressure, or for growth on medium which is deficient in an appropriate nutrient when auxotrophy is used as the selective pressure. Expression of the heterologous protein may be optimized using known methods. The BMP thus obtained will be present in insoluble, refractile inclusion bodies which may be found in pellets of disrupted and centrifuged cells.
The inclusion bodies thus obtained are then solubilized using a denaturant or by acidification with acetic acid or trifluoroacetic acid. If solubilized using a denaturant, a reducing agent such as /-mercaptoethanol or dithiothreitol is added with the denaturant. If the protein is solubilized by acidification, it must be reduced prior to acidification. The solubilized heterologous protein may be further purified using known chromatographic methods such as size exclusion chromatography, or exchange chromatography, or reverse phase high performance liquid chromatography.
The solution containing the BMP is then reduced in volume or vacuum desiccated to remove chromatography buffer, and redissolved in medium [suitable media include 50 mM Tris, 1.0 M NaC1, 2% 3-(3-chlolamidopropyl)dimethylammonio-l-propane-sulfate (CHAPS), 5 mM EDTA, 2 mM gluatathione (reduced) 1 mM glutathione (oxidized); at pH of approximately other media which may be suitable for redissolution include alternative refolding buffers described elsewhere in the specification guanidine, urea, arginine)] to yield a concentration of 1 to 100 jyg/ml protein. Higher concentrations of protein may be refolded in accordance with the invention, for example up to about 1 mg/ml, but precipitates or aggregates are present above protein concentrations of 100 xg/ml and the yield of active BMP homodimer or heterodimer may be decreased accordingly.
I
WO 95/16034 PCTIUS94/13181 For production of heterodimers, the above procedure is performed utilizing equal amounts of two plasmids, each containing a coding sequence for a distinct BMP pALBP2, encoding BMP-2 and pALBPX encoding BMP-X, where X is 5, 6, 7 or The plasmids are cultured separately, and the resulting inclusion bodies are solubilized and refolded in accordance with the methods described herein. The refolded protein monomers are mixed together in equivalent ratios and treated as described in the paragraph above. For heterodimers, the media uses CHAPS as the refolding buffer. The resulting dimeric proteins are observed to include homodimers of BMP-2, as well as heterodimers of BMP-2/X. These species may be separated out from each other through procedures known in the art. The production of heterodimers of BMP is more thoroughly described in W093/09229, the disclosure of which is hereby incorporated by reference.
In order to refold the proteins, the following conditions and media may be used: 50 mM Tris, 1.0 M NaCI, 2% 3-(3-chlolamido-propyl)dimethylammonio-1propane-sulfate (CHAPS), 5 mM EDTA, 2 mM gluatathione (reduced) 1 mM glutathione (oxidized); at pH of approximately 8.5. With minor modifications, other detergents, including non-ionic, e.g. digitonin, or zwitterionic detergents, such as 3- (3-chlolamidopropyl)dimethylammonio-l-propane-sulfonate (CHAPSO), or N-octyl glucoside, may be used in the present invention, One skilled in the art will recognize that the above conditions and media may be varied, for example, as described below.
Such variations and modifications are within the present invention.
Because BMPs are disulfide bonded dimers in their active state, it is useful to include a redox system which allows formation of thiol/disulfide bonds in the method of the invention. Several such redox systems are known. For example the oxidized and reduced forms of glutathione, dithiothreitol, -mercaptoethanol, /3mercaptomethanol, cystine and cystamine may be used as redox systems at ratios of reductant to oxidant of about 1:10 to about 2:1, When the glutathione redox system is used, the ratio of reduced glutathione to oxidized glutathione is preferably 0.5 to more preferably 1 to 1; and most preferably 2 to 1 of reduced form to oxidized form.
With additional modifications, other refolding agents, such as urea, guanidine, arginine and other means of refolding, may be useful in order to produce correctly
I
II– WO 95/16034 ‘PCT/US94/13181 refolded proteins with the mutants of the present invention. Chaotropic agents are generally used at concentrations in the range of 1 to 9M. When urea is the refolding agent, it is preferably present at concentrations in the range of about 0.1M to about 3M, more preferably about 0.5M to 2.5M, or about 1O.M to about When guanidine hydrochloride is used as the refolding agent, it is preferably initially added at high concentration., for example, 7-8M, and then the concentration of guanidine is reduced to induce refolding. The reduction of guanidine concentration may occur instantaneously, as by dilution, or gradually, as by dialysis. Preferably the guanfiine concentration is reduced to a final concentration of less than about 1.5M, or more preferably less than about 1M. When the guanidine concentration is reduced gradually, the guanidine may be completely removed from the refolded protein. Dilution of a guanidine is preferable over dialysis.
When arginine is used as the refolding agent, it is preferably present at concentrations of about 0.4M to about 1.5M, more preferably, about 0.6M to about 1.25M, or about 0.6M to about 1.OM.
In addition to the refolding agent, the method of the inventior may employ a salt moiety. When detergents, such as CHAPS, are used, the salt moiety is preferably NaCI, preferabi» at a concentration of about 0.5M to about preferably about 1.0M. When urea is the refolding agent, the salt moiety is preferably sodium chloride, preferably at a concentration of about 0.25M to about 2M. More preferably, the sodium chloride is present at a concentration in the range of about 0.5M to about 1.5M when urea is the refolding agent. Most preferably, when urea is the refolding agent, sodium chloride is present at a concentration in the range of about 0.75M to about 1.25M. When guanidine is used as the refolding agent, the sodium chloride concentration must be increased as the concentration of guanidine increases, For example, for refolding in 0.2M guanidine, the range of NaCI concentration which is optimal is 0.25 to 0.5M, while for refolding in 1.OM guanidine, 1.0 to 2.0M NaCI is necessary for optimal refolding.
The pH of the refolding reaction of the present invention when urea is the refolding agent is preferably from about 7.5 to about 11: more preferably from about to about 10.5. When detergents such as CHAPS, are used as the refolding agent, the preferred pH is about 8.5. When guanidine is used as the refolding agent, the pH
I
WO 9,9116034 WO 95)6034 1C-TW9J941131 81 is pr~e ably from about 7,5 to about more preferably about 85s; and miost preferably about 93-. W’hen atgino is used as thfe refolding agent, the pH1 is preferably from about 8 io about 1og, more preferably from about 8.5 to about 10. and most preferably from about 9.3 to about Preferably, the refolding reaction of the invention is performed at a temperatmra range from about 411C to about 23 0 C. More preferably. die refolding reaction is performed at 4 0 C. The refolding reactions of the present invention are allowed to proceed to completion, preferably &ibout 16 hiour&~ The extent of refolding of bone morphogenetic proteins obtained is monitored by sodium dodecyl sulfate-pol~yacrylamide electrophoresis (SDS-PAGE) under nonreduced and reduced conditions. The RIMPA4 homodimer will appear as a band of about 30 kI) under non-reduccd conditions on a 16 percent S)Supolyacrylamiude Sol, and tie JIMPA monomer ppears as a band of about 13 kD) under reduced conditions.
The BIMP-2/S hererodiiner will appear as a band of about 35 kI) under non-reduced conditions on a 16 percent SDSpolyacrylamide gel-, the BMP-2 monomer appears as a band of about 13 ID under reduced conditions;- and the BMP-5 monomer appears as a band of about 15 ID) under reduced conditions. The BMP-2/6 hieterodimer will appear as a band of about 35 ID under nort-reduced conditions on a 16 percent SDSpolyacrylainide gel;, the BMP-2.monomer appears as a band of about 13 kD under reduced cenditions; and thie DNMP-6 monomer appears as a band of about 15 kD under reduced conditions. The BMP-2/7 heterodimrer will appear as a band of about 35 ki under non-reduced conditions on a 16 percent S-polyacrylamide gel; the IIMP-2 monomer appears as a band of about 13 D under reduced conditions-, and the DMP-7 monomer appears as a band of about 15 kD) under reduced conditions.
The fit vitro biological activity of dhe refolded bone morphogenctic proteit is monitored by the W-20 assay as sdt forth inBxarnpla 9. Use of die W-2017 bone marrow stromal cells as an indicator cell line is based upon die conversion of these elils to osteoblast-like cells after treatment with BMP [RI S. Thies et at.. Journal, or Done and Minerot Researchi &2A4305 (1990)A and R Thies et aL. E~ndocrinology 130:1318-1324 (1992)]. NY-20-17 cells are a elonal bone marrow stromal cell line derived from adult mice by researchers; in the laboratory of Dr. D. Natitan, Children’s Hospital, Boston. MA, Treatmnent of NWP20-7 cells with lIMP results in WO 9511034 ~YO 9)1603 Pc’1US94113181 increased alkaline phosphatase production, indt ~A parathyroid hormone stimulated cAM1P, and (3M induction of osteacalcin synthesis by the fells. While (1) and, represent characteristics assoriated with dhe osteoblast phenotype, the ability to synthesize osteocalcin is a phenotypic propea’y only displayed by mature 6 ostcoblasts. Furthermore, to date the conversion of W-20-17 stromal cells to osteoblast-1ike cells has been observed only upon treatment with bone morphogenetic proteins. The in vivo biological activity of the refolded bone morphogenetic proteins is monitored by a modifi.-d version of the rat bone formation assay described in Sampath and Reddi. Proc. NatI. Acad, Sci, USA, L:691-659S (1983) herein called the Rosen-modified Sampath-Reddi assay, as set forth, in Example Example 1 RcfodinDMP_-4usinC APm cm g of cells stored at -8011C are measured. Solution (3.4 ml 100mM TRIS, 10mM EDTA, PH 8,5) is added. The solution is vortexed until cells are well suspended. 40 jdl 100 mM PMSF in isopropanol is added, The cells are lysed at 1000 psi in a French pressure cell. The inclusion bodies are centrifuged at 4’C for minutes in an Epper’Jorlf microfage to form pellets. The supernatants are decanted. To one pellet (out of 4 total) 1.0 nml degassed 8.OM guanidine hydrochloride, MIAM TRIS, 5mM EDTA, p11 8.5, containing 250mM DTT is added.
The pellet is dissolved and argon is blown over the liquid for 30 seconds. Next the solution is incubated at 37 0 C for one hour. Insoluble material is pelleted for 2-3 minutes in an Eppendorf microfuge at 23 0 C. 0.5-1.0 ml of supernatant is injected onto a Supelco 2 cmn guard cartridge (LC-304), and eluted with an acetonitrile gradient in 0.1%1″ TFA from 1-70% over 35 minutes. 13MP-4 elutes between 30 and 32 minutes. Fractions are pooled and the protein eoncentration determined by A280 versus 0. 1% TPA, using the theoretical extinction coeffecient based upon the amnino acid content.
A sufficient volume of the BMP-4 pool is lyophilized to give 10 tg, of protein.
5 lil of glast distilled water is added to redissolve the residue, then 100 ti1 of refold mix (TR1S, salt, CHAPS, etc.) is added, The solution is gently mixed and stored at 23TC for 1-4 days. Dimer formation is assessed by running an aliquot on a Novex WO 95/16034 PCT/US94/13181 16% tricine gel at 125 volts for 2.5 hours, followed by Coomassie Blue staining and destaining.
Example 2 Refoding of otherBMP dimer From an examination of Figure 1, it can be seen that BMP-2 and BMP-4 are highly homologous, beginning at the first cysteine (residue 14 of BMP-2; correlative residue 16 of BMP-4). There are only eight correlative residues which are different.
These are, respectively, at residues 15, 39, 46, 73, 95, 96 and 105 of BMP-2. Yet, Applicants have found that BMP-4 that the methods disclosed in EP 0433225, which are effective for refolding BMP-2 in acceptable quantities, produce undesirably low yields of correctly folded, biologically active dimeric protein when applied to bacterially produced BMP-4. Applicants constructed molecules in which the first four (N-terminal) of these residues resembled the BMP-2 residue, while the last four (Cterminal) of these residues resembled the correlative BMP-4 residue (called «BMP- 2/BMP-4»). Applicants also constructed molecules in which the N-terminal four of these residues resembled BMP-4, while the C-terminal four of these residues resembled the correlative BMP-4 residue (called «BMP-4/BMP-2»). These molecules were worked up as described for wild-type BMP.4 above. Gels were run with the appropriate control proteins the BMP-4 mutants next to wild-type BMP-4; BMP-2 and wild-type BMP-5 mixed together as a control for the BMP-2 and BMP- 5(A56His).
Wild-type BMP-4 did not refold well. While BMP-4/BMP-2 refolded in good yield; however, BMP-2/BMP-4 does not, BMP-4(A107Asp) homodimer refolds in good quantity relative to wild-type BMP-4.
BMP-2/BMP-5 heterodimer does not refold well. BMP2/BMP5(A39HIS) heterodimer refolds in good quantity relative to BMP-2/BMP-6 heterodimer does not refold well. BMP2/BMP6(A39His) heterodimer refolds in good quantity relative to BMP-2/BMP-6.
Example 3 Expression of BMP in E. coli An expression plasmid pALBP2-782 containing the following principal features was constructed for production of BMP-2 in E. coli. Nucleotides 1-2060 contain WO 95/16034 PCVUS94113181 DNA sequences originating from the plasmid pUC-18 (Norrander et al., Gene 26:101-106 (1983)] including sequences containing the gene for f-lactamase which confers resistance to the antibiotic ampicillin in host E. coli strains, and a colElderived origin of replication. Nucleotides 2061-2221 contain DNA 5 sequences for the major leftward promotor (pL) of bacteriophage X [Sanger et al., J. Mol. Biol.
162:729-773 (1982)], including three operator sequences O.l1 0 2 and 0,3. The operators are the binding sites for Xcl repressor protein, intracellular levels of which control the amount of transcription initiation from pL. Nucleotides 2222-2723 contain a strong ribosome binding sequence included on a sequence derived from nucleotides 35566 to 35472 and 38137 to 38361 from bacteriophage lambda as described in Sanger et al., J. Mol. Biol. 162:729-773 (1982). Nucleotides 2724-3133 contain a DNA sequence encoding mature BMP-2 protein with an additional 62 nucleotides of 3′-untranslated sequence. Nucleotides 3134-3149 provide a «Linker» DNA sequence containing restriction endonuclease sites. Nucleotides 3150-3218 provide a transcription termination sequence based on that of the E. coli a~ A gene [Takagi et al., Nucl, Acids Res. 11:2063-2074 (1985)]. Nucleotides 3219-3623 are DNA sequences derived from pUC-18, Using restriction endonucleases and procedures known in the art, one can readily replace the coding sequence for BMP-2 contained in pALBP2-781 with the coding sequence for another BMP c'»ired to be produced in E. coli. With this substitution in the pALB2-781 plasmid, the following examples may be used to express and refold any of the BMPs of the present invention. Plasmid pALBP2- 781 was transformed into the E. coli host strain GI724 lac 1 l, JlcpL8, ampC::Xcr) by the procedure of Dagert and Ehrlich, Gene 6:23 (1979). GI724 (ATCC accession No, 55151) contains a copy of the wild-type Xcl repressor gene stably integrated into the chromosome at the japC locus, where it has been placed under the transcriptional control of Salmonella typhimurinum it promotor/operator sequences. In GI724, XCI protein is made only during growth in tryptophan-free media, such as minimal media or a minimal medium supplemented with casamino acids such as IMC, described above. Addition of tryptophan to a culture of GI724 will repress the trp promoter and turn off synthesis of Xcl, gradually causing the induction of transcription from pL promoters if they are present in the cell.
WO 95/16034 PCT/US94113181 Transformants were selected on 1.5% w/v agar plates containing IMC medium, which is composed of M9 medium [Miller, «Experiments in Molecular Genetics,» Cold Spring Harbor Laboratory, New York (1972)] supplemented with 1mM MgSO 4 0.5% w/v glucose, 0.2% w/v casamino acids and 100 pg/ml ampicillin and GI724 transformed with pALBP2-781 was grown at 370 C to an A 55 0 of 0.5 in IMC medium containing 100 pg/ml ampicillin. Tryptophan was then added to a final concentration of 100 ig/ml and the culture incubated for a further 4 hours on ampicillin-containing medium. During this time BMP protein accumulates to approximately 10% of the total cell protein, all in the «inclusion body» fraction.
Nine grams of frozen cell pellets obtained from the E. coli transformants as described above were thawed in 30 ml of TE8.3(100:10) buffer (100 mM Tris-HCI pH 8.3, 10 mM NaEDTA, 1 mM phenylmethylsulfonyl fluoride Cells were lysed by three passes through a MicrofluidizerT» [model #MCF 100 The lysate was diluted to approximately 120 ml with TE8.3 100:10 buffer. A pellet of inclusion body material was obtained by centrifugation at 15,000 x g. The supernatant was decanted, and the inclusion body material was suspended in 50 ml TE8.3(100:10) which also contained 1% Triton-X100. The resuspended inclusion bodies were centrifuged for 10 minutes at 15,000 x g, and the supernatant was decanted. The pellet was suspended in TE8.3(20:1) buffer (20 mM Tris-HCI pH 8.3, 1 mM Na 2 EDTA, 1 mM PMSF) which also contained 1% dithiothrietol [DTT].
After the suspension was homogenized in a Wheaton glass homogenizer, it was acidified to pH 2.5 with glacial acetic acid and then centrifuged 25 minutes at 15,000 x g. The supernatant from this centrifugation was collected and chromatographed over a Sepharose S-100T» size exclusion column (83 cm x 2.6 cm; =440 ml bed) in 20 ml increments. The Sepharose S-100TM column was run with a mobile phase of 1% acetic acid at a flow rate of 1.4 ml/min. Fractions corresponding to BMP-2 monomer were detected by absorbance at 280 nm, and using a computer calculated extinction coefficient of 18200M'»cm and molecular weight (12777 daltons). This size exclusion column pooled material was used as starting material for refolding reactions.
Alternatively, cells were lysed as above, but the initial inclusion body material pellet was dissolved in 8 M guanidine-HC1, TE8.5(100:10) buffer (100 mM Tris-HCl WO 95/16034 PCT/US94/13181 pH 8.5, 10 mM NaBEDTA *which contained 100 mM DTT, and incubated at 37 0
C
for 1 hour. This material was centrifuged at 12.000 x g for 15 minutes at room temperature. The supernatant was injected onto C4 analytical RP-HPLC (reversed phase-high performance liquid chromatography) column (Vydac 214TP54) equilibrated to 1% B buffer (A buffer 0.1% trifluoroacetic acid, B buffer acetonitrile, 0.1% trifluoroacetic acid with a flow rate of 1 ml/min. After minutes, a linear gradient from 1% to 70% B buffer (diluted into A buffer) was run over 35 minutes, during which time the protein elutes. Protein was monitored by absorbance at 280nm. Peak BMP-2 fractions (eluting between 25 and 35 minutes) were pooled. The concentration was determined by absorbance at 280nm, and using the computer calculated extinction coefficient and molecular weight as indicated above. This RP-HPLC C4 Column pooled material was also used as starting material for refolding reactions.
Example 4 Refolding of coli Produced BMP-2 in Urea/NaC BMP-2 protein in 1% acetic acid or in reverse phase buffer containing 0.1% TFA, 30-40% acetonitrile was dried or reduced in volume using a speed vacuum, redissolved with a few microliters of 0.01 TFA, and allowed to dissolve completely for 5 to 10 minutes. A buffer containing 7M to 8M urea, 100 mM 2-(Ncyclohexylamino)-ethanesulfonic acid [CHES] pH 9.5, 5 mM EDTA was added to the BMP-2 in TFA and allowed to incubate for 20 minutes at room temperature (RT, approximately 23°C) before dilution. The protein concentrations used were such that the final BMP-2 concentration in the diluted f.ate was 10 to 100 Ag/ml. The final conditions of the folding buffer contained 100 mM CHES, 5 mM EDTA, and the desired concentration of salt for the urea concentration used. Several ranges of urea, NaC1, pH, and redox conditions were tested to optimize BMP-2 refolding conditions.
Refolding of the E. coli produced BMP-2 in urea/NaCl was analyzed under reducing and non-reducing conditions using 16% Tricine-sodium dodecyl sulfate polyacrylamide electrophoresis (SDS-PAGE).
Refolding was scored as positive when the BMP-2 appeared as a dimer of the appropriate molecular weight under non-reducing conditions and as a monomer of WO 95/16034 PCTIUS94/13181 appropriate molecular weight under reducing conditions- Yield of refolded BMP-2 was determined by scanning bands on loomassie blue or silver stained gels.
Biological activity of the refolded BMP-2 dimer was tested using the assays of Examples 9 and 10 below.
Refolding of Efoi produced BMP-2 in urea and NaCI optimally occurred at ranges of 1.0 to 2.0 M urea and 0.75 to 1.25 M NaCI. SDS-PAGE bands of medium intensity were observed within concentration ranges of 0.5 to 1.0 M and 2.0 to M urea and 0.5 to 0.75 M and 1.25 to 1.5 M NaCl. Faint bands corresponding to refolded BMP-2 were observed to occur at concentrations in ranges of 0.1 to 0.5 and 2.5 to 3 M urea and 0.25 to 0.5 and 1.5 to 2 M NaCl. Refolding of BMP-2 occurred within the pH range of 7.5 to 11, with better refolding in the pH range of 8,5 to 10.5 and optimal refolding in the pH range of 9 to Example Refolding ofE. coli Produced BMP-2 in GuanidineNaCl BMP-2 protein in 1% acetic acid or in reverse phase buffer of 0.1% TFA,, 30-40% acetonitrile was dried or reduced in volume to remove acetonitrile using a speed vacuum, redissolved with four microliters 0.01 TFA and allowed to dissolve completely for 5 to 10 minutes. A solution containing 8 M to 8.5 M guanidine HCI (guanidine), 100 mM CHES pH 9.5, 5mM EDTA was added to the BMP-2 in TFA and allowed to incubate for 20-30 minutes at room temperature before dilution. The protein concentrations used were such that the final protein concentration in the diluted state was 10 to 100 pg/ml.
The guanidine/BMP solution was diluted into a chilled folding buffer (on ice) with the appropriate amount of NaCI and with 50-100 mM CHES pH 9.5, 5 mM EDTA, 2 mM reduced glutathione (GSH), 1 mM oxidized glutathione (GSSG).
Samples were argon bubbled (15 seconds) while on ice, and incubated at 4°C.
Refolding of the E. col produced BMP-2 in guanidine was analyzed under reducing and non-reducing conditions using Tricine-SDS-PAGE as described above in Example 4.
Refolding of E. coli produced BMP-2 in guanidine optimally occurred at ranges of 0.18 to 1.0 M guanidine. SDS-PAGE bands of medium intensity were
I
WO 95/16034 PCMIUS4I4II8 observed within concentration ranges of 0 to 0.18 M and 1.0 to 1.25 M guanidine.
Faint bands corresponding to refolded BMP-2 were observed to occur at concentrations in ranges of 1.25 to 1.SM guanidine. Refolding of BMP-2 occurred in guanidine within the pH range of 7.5 to 9.5, with better refolding at pH 8.5 and optimal refolding at pH 9.5. Refolding of BMP-2 was optimal at 40C, though some refolding was observed at room temperature. (approximately 23 Example 6 Refolding of E, coli BMP-2 in Areinine/NaCI BMP-2 protein in 1% acetic acid or in reverse phase buffer of 0.1% TFA, 3acetonitrile was dried or reduced in volume to remove acetonitrile using a speed vacuum, redissolved with four microliters of 0.01% TFA and llowed to dissolve completely for 5 to 10 minutes. The protein concentrations used were such that the final protein concentration in the folding buffer was 10 to 100 &ig/ml. The folding buffer contained 100 mM buffer titrated to the appropriate pH, 5 mM EDTA, and the desired concentration of salt. Refolding of the E. coli produced BMP-2 in arginine was analyzed under reducing and non-reducing conditions using Tricine-SDS-PAGE as described above in Example 4. Substantial bands were observed at all concentrations of arginine used to refold BMP-2; however, the greatest yield of BMP- 2 was obtained using 0.6 to 0.8 M arginine and from 0 to 0.25 M NaCl. Several types of salt were tested for ability to enhance BMP-2 refolding: NaCI, MgCI,, MgS0 4 NaS04. Of these, NaCl and MgCl, yielded optimal amounts of refolded BMP-2, and MgS0 4 yielded intermediate amounts of refolded BMP-2. The optimal pH range for refolding BMP-2 in arginine is pH 9.5 to 10. Refolding also occurred at pH 3.5. Refolding BMP-2 in arginine was optimal at 40, though some refolding was observed at room temperature (approximately 23*).
Example 7 Refolding of BMP-2 Using Organic Alcohols Denatured, monomeric BMP-2 (and BMP-6) in 1% acetic acid, prepared as previously described, were added to an Eppendorf tube and lyophilized to dryness.
The pellets were redissoived in 20 ul of 0.01% trifluoroacetic acid. 500 ul of buffer was then added, containing 50 mM Tris (pH 5 mM EDTA, 1.0 M NaC1, 2 mM reduced glutathione, 1 mM oxidized glutathione, and 10-20% methanol, ethanol, or ~1_1_ WO 95/16034 PC/US94/13181 isopropanol. Samples were incubated at room temperature for three days, the evaluated for dimer formation by SDS-PAGE on a 16% Novex tricine gel. A small but discernible amount of BMP-2 dimer was detected after staiining with silver. There was no evidence of any BMP-2/6 heterodimer of BMP 6/6 homodimer on the same gels.
Example 8 Purification of Dimeric BMP-2 Urea refolded BMP-2 protein was injected onto a HPLC C4 analytical column (Vydac 214TP54) equilibrated to 10% B buffer (A buffer 0.1% TFA, B buffer 95% acetonitrile, 0.1% TFA), with a flow rate of 1 ml/min. After 15 minutes, a linear gradient from 10% to 50% 13 buffer was applied over 40 minutes, during which time the dimeric BMP-2 protein eluted. Protein was monitored by absorbance at 280 nm. Peak BMP-2 dimer fractions (eluting between 45 and 48 minutes) were pooled, analyzed by 16% Tricine-SDS-PAGE, and tested for biological activity in the assays described in Examples 9 and Example 9 Alkaline Phosphatase Assay Protocol W-20-17 cells are plated into 96 well tissue culture plates at a density of 10,000 cells per well in 200 pl of medium (DME with 10% heat inactivated fetal calf serum, 2 mM glutamine). The cells are allowed to attach overnight in a 95 air, 5 co 2 incubator at 37 0
C.
The 200 l1 of medium is remo\ ed from each well with a multichannel pipettor and replaced with an equal volume of test sample delivered in DME with 10% heat inactivated fetal caif serum, 2 mM glutamine and 1% penicillin-streptomycin.
The test samples and standards are allowed a 24 hour incubation period with the W-20-17 indicator cells. After the 24 hours, plates are removed from the 37 0
C
incubator and the test media are removed from the cells.
The W-20-17 cell layers are washed three times with 200 Al per well of calcium/magnesium free phosphate buffered saline and these washes are discarded.
50 1 of glass distilled water is added to each well and the assay plates are then placed on a dry ice/ethanol bath for quick freezing. Once frozen, the assay plates are removed from the dry ice/ethanol bath and thawed at 37 0 C. This step is Ir WO 95/16034 PCTUS94/13181 repeated two more times for a total of 3 freeze-thaw procedures. Once complete, the membrane bound alkaline phosphatase is available for measurement pC of assay mix (50 mM glycine, 0.05% Triton X-100, 4 mM MgCl, mM p-nitrophenol phosphate, pH 10.3) is added to each assay well and the assay plates are then incubated for 30 minutes at 37°C in a shaking waterbath at oscillations per minute.
At the end of the 30 minute incubation, the reaction is stopped by adding 100 jil of 0.2 n NaOH to each well and placing the assay plrtes on ice.
The spectrophotometric absorbance for each well is read at a wavelength of 405 nanometers. These values are then compared to known standards to give an estimate of the alkaline phosphatase activity in each sample. For example, using known amounts of p-nitrophenol phosphate, absurl ance values are generated. This is shown in Table I.
WO 95/16034 WO 9516034PCTIUS94II318I Table I Absorbance Values for Known Standards of P-Nitrophienol Phosphate_____ P-nitrophenol Phosphate p~moles Mean Absorbance (403 n) 01000 0 0.006 0.261 -=.024 0.012 0.521 +/-.4031 0.018 0.797 .063 0.024 1,074 .061 0.030 1.305 .083 Absorbance values for known amounts of BMP-2 can be determnined and converted to jimoles of p-nitrophenol phosphate cleaved per unit time as shown in Table II.
Table 11 Alkaline Phosphatase Values for W-20 Cells Treated wihh J3MP-2 J3MP-2 concentration Absorbance, Reading unioles substrate ng/ml 405 nmneters per hour 0 0.645 0.024 1.56 0.696 0.026 3.12 0.765 0.029 6.25 0,923 0.036 12.50 1.121 0.044 25.0 1.457 0.058 50.0 1,662 0.067 100.0 1.977 0.08 WO 95/16034 PCTIUS94/13181 These values are then used to compare the activities of known amounts of BMP heterodimers to BMP-2 homodimer.
Example Rosen-Modified Sampat hReddi Assay The ethanol precipitation step of the Sampath-Reddi procedure, supra, is replaced by dialyzing (if the composition is a solution) or diafiltering (if the composition is a suspension) the fraction to be assayed against water. The solution or suspension is then redissolved in 0.1 TFA, and the resulting solution added to mg of rat matrix. A mock rat matrix sample not treated with the protein serves as a control. This material is frozen and lyophilized and the resulting powder enclosed in #5 gelatin capsules. The capsules are implanted subcutaneously in the abdominal thoracic area of 21-49 day old male Long Evans rats. The implants are removed after 7-14 days. Half of each implant is used for alkaline phosphatase analysis [see, A. H. Reddi, et al., Proc. Natl. Acad. Sci., 69:1601 (1972)] The other half of each implant is fixed and processed for histological analysis.
One pm glycolmethacrylate sections are stained with Von Kossa and acid fuschin to score the amount of induced bone and cartilage formation present in each implant.
The terms +1 through +5 represent the area of each histological section of an implant occupied by new bone and/or cartilage cells and matrix, A score of indicates that greater than 50% of the implant is new bone and/or cartilage produced as a direct result of protein in the implant. A score of and +1 would indicate that greater than 40%, 30%, 20% and 10% respectively of the implant contains new cartilage and/or bone.
WO 95/16034 PCT/US94/13181 SEQUENCE LISTING GENERAL INFORMATION: APPLICANT: GENETICS INSTITUTE, INC.
(ii) TITLE OF INVENTION: MUTANTS OF BONE MORPHOGENIC PROTEINS (iii) NUMBER OF SEQUENCES: 12 (iv) CORRESPONDENCE ADDRESS: ADDRESSEE: Genetics Institute, Inc Legal Affairs STREET: 87 CambridgePark Drive CITY: Cambridge STATE: Massachusetts COUNTRY: USA ZIP: r2140 COMPUTER READABLE FORM: MEDIUM TYPE: Floppy disk COMPUTER: IBM PC compatible OPERATING SYSTEM: PC-DOS/MS-DOS SOFT’ARE: Patentin Release Version #1.25 (vi) CURRENT APPLICATION DATA: APPLICATION NUMBER: FILING DATE:
CLASSIFICATION:
(vii) PRIOR APPLICATION DATA: APPLICATION NUMBER: US 08/163,877 FILING DATE: December 7, 1993 («iii) ATTORNEY/AGENT INFORMATION: NAME: Lazar, Steven R.
REGISTRATION NUMBER: 32, e REFERENCE/DOCKET NUMBER: GI 5219-PCT (ix) TELECOMMUNICATION INFORMATION: TELEPHONE: 617 498-8260 TELEFAX: 617 876-5851 INFORMATION FOR SEQ ID NO:1: SEQUENCE CHARACTERISTICS: LENGTH: 342 base pairs TYPE: nucleic acid STRANDEDNESS: double TOPOLOGY: unknown (ii) MOLECULE TYPE: DNA (vi) ORIGINAL SOURCE: ORGANISM: bmp-2 (ix) FEATURE: NAME/KEY: CDS LOCATION: 1..342 (xi) 9EQUENCE DESCRIPTION: SEQ IP NO:1: CAA GCC AAA CAC AAA CAG CGG AAA CGC CTT AAG TCC AGC TGT AAG AGA Gln Ala Lys His Lys Gin Arg Lys Arg Leu Lys Ser Ser Cys Lys Arg 1 5 10 CAC CCT TTG TAC GTG GAC TTC AGT GAC GTG GGG TGG AAT GAC TGG ATT His Pro Leu Tyr Val Asp Phe Ser Asp Val Gly Trp Asn Asp Trp Ile 25 WO 95116034 1PUS94/13181
GTG
Val
TTT
Pho
ACO
Th
CCO
Pro
AAG
Lys
TGT
Cys (2) Gin 1 His Val Phe Thr Pro Lys Cys (2) OCT CCC CCO GGG TAT CAC GC TTT TAC Ala Pro Pro Gly Tyr His Ala Phe Tyr 40 CCT CTG GCT GAT CAT CTO AMC TCC ACT Pro Lou Ala Asp His Lou Ann Ser Thr 55 TTG GTC AAC TCT OTT AAC TCT AAG ATT Lou Val Ann Ser Val Ann So? Lys lie 70 ACA GAA CTC AGT G»T ATC TCO ATG CTG Thr Olu Lou Ser Ala Ile Ser Met Lou 90 OTT OTA TTA AAG AAC TAT CAG GAC ATO Val Val Lou Lyn Ann Tyr Gin Asp Met 100 105
CGC
Arg INFORNATICN FOR SEQ ID NO:2: SEQUENCE CHARACTERISTICS: LENGTH: 114 amino acids TYPE: amino acid TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID Ala Lyn His Lys Gin Arg Lys Arg Lou s Pro Lou Tyr Val Asp Phe 5cr Asp Val 25 Ala Pro Pro Oly Tyr Min Ala Phe Tyr Pro Leu Ala Asp His Lou Ann Ser Thr f SO 55 Lou Val Ann Ser Val Ann Sor Lys lie I 70 Thir Glu Lou Sor Ala lie Ser Met Lou I Val Val Lou Lyn As Tyr Oln hop Met C 100 L05 Arg INFORMATION FOR SRQ ID NO:3: SEQUENCE CHARAW TBRISTICS: LENGTH: 348 base pairs TYPE: nucleic acid STRANDEDNESSt double TOPOLOGY: %inknown TO C Cys
MAT
Aon
CCT
Pro 75
TAC
Tyr Gr Val CAC OGA GAM His Gly Glu CAT 0CC ATT Hi.s Ala le MAG GCA TGC Lys Ala Cys CTT GAC 5AG Lou Asp Glu OTG GAG GOT Val Olu Oly 110
TGC
Cyn
GTT
Val.
TOT
Cya
AAT
Asn
TGT
Cys
CCT
Pro
CAG
Oln
GTC
Val
GAA
Glu
GGG
Gly 144 192 240 288 336 02 iys Ser -ly Trp lys His ksn His ?ro Lyn 75 ryr Lou lal Val Cy.
Asp Olu Ile Cys Glu Gly 110 Arg lie Pro Gin Vaal Glu Gly wo 9916034 WO 9516034 CTIIS941E318,1 UOWL~gUr TYP. NI Ivi) CBPTOZUAL GCMflZ till) FCTAVRE.34 SEQUUMBf MO)RIPTIC»12 83; :1 ID AjfMTAX-1 CAT (gf TVA CA9 11-i AAg, AAg AAT AAg A T3 Car Pro Lys Hiila Dar Gin Arg Ala Arcl Lys Lynr Lyn Ann Caa I 1 21U9S CGfJ C02 CAI TCJ CTO TA7T GTO GA9 TT4 X39 OAT OT3 OW T~ 533AT GAV Argj Arg Ilia Der Lou Tyr Val Asp Phe Bar Asp Val (Jip Trp Ann Asp 210 2 1 T63 ATI’ GTI ‘2C CMA CZA =N TA9 CAS 699 TV~ TAC Tsaf CAT GB3 GAC Trp 11a Val Ala Pro, Pro Gly Tyr Gin Ala Pha Tyr Cya lila Gly Asp 48 4S TOO CCC TTT CCA MT, OCT GAO CAC C’C AA1 TOA A= AM: CAT 6 ATT cya Pro Plia Pro Lou Ala AOp Ilia Lou Ann nor Thr Ann Ilia Ala Ile so 99 GTOS CAO ACC CTO GTG* AAT TCT G70 MAT TCC AWT ATC CCC AMA GCC TGT Val Oln Thr Lou Val Arm nar Val Ann Der Gar Ile Pro Lys Ala Cyo 710 75 0 TGuT GTO CCC ACT GMA CTO A 3T OCC ATC TCCl ATJ CM~ TAC9 CT3 GAT GAO Cyo Val Pro Thr GiU Lou Gar Ala Ile Oar Mot Lou Tyr Lou Asp (li as 90 99 TAT GAT AA9 GTJ OTh MT~ AMA MT TAT CAI GA3 AT91 OTA GTA GA9G OA Tyr Asp Lys Val Val Lou Lys Ann Tyr Gin Olu Moat Val Vali Glu Gly 100 105 110 TOT G33O T4BC COC Cya alp Cys Arg 113 NOPIATWON FOR 9E7Q 10 N014.- Si EQUIMCI CIlARCTERIBTXCBa MAIGTH 116 amino acids TYPI,, amino acid TOPOVYV: linecar (ji) fj*~ YPEM protein (xti) BCEO= DMMIPTIO.N =0 ID Der pro Lyn ilia ilia Car Oln Arg Ala Arg %yn Lys Arm Lys Ann Cya 1 Be 10 1 I Argj Arg Mei Baor Lou Tyr Vtal AaP P110 Dar Anp Val Gly Trp Ann Afnp 29 Trp Ile Val Ala pro Pro Gly Tyr Gin Ala Pht Tyr Cya Hisr aly Asp 391 40 4S Cyo Pro Pho Pro Lou Ala Anp 1110 Lou Ann Der Thr Ann Ilin Ala Ile so .55 96 144 192 240 280 336 340 WO 95116034w PCT1SS94113181 Val Cyn Tyr Cyn (2) Gln Tkr Lou Val Ann Bar Val Ann Dar Bar Ile Pro Lyn Ala Oyo 75 00 Val Pro Thr Glu Lou Bar Ala Ile Bar Mt Lou Tyr Lou Asp GIu 09 Do Asp Lys Val Val Lou Lyn Ann Tyr Gin Glu NMat Val Val Oiu Gly 100 105 110 Gly Oya Axg 115 INFORMATION FOR SEQ ID SEQUENCE CHA14A0TERISTICS: LENGVTH: 396 base pairo TYPE: nucleic acid STRAN’DEDNESS: double TOPOLOGY: linear (ii) MOLECULE TYPE: AN (vi) ORIGINAL SOURCE: ORGANISM: bnp-S (ix) FEATURE: NAME/KEY: CDS LOCATION: 1..396 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:S: AAT CAA AAC COO Asn Gin Ann Avg 1
TCO
Oar
AAG
Lys
AT?
TOT
Bar 635
CAG
Gin
TOT
Cys
AGC
Bar
TOT
Cyn AO? OTT OA Der Val Gly CAC OAk CTC His IU, LOU ATA OCA CCA 110 Ala Pro s0 TT OCA CT? Pho Pro Lou ACT CTO OTT Thr Lou Val OCT CA AC Ala Pro Thr 100 TCC AAT OTC Oar Ann Val 115 GGC TOO CAC Gly Cyn lilt 130 MAT AAA TC Ann Lyn Oar 5 OAT TAT MOC Asp Tyr Ann TAT OTO AGO Tyr Val Oar OAA GOA TAO Glu Gly Tyr 55 MC 000 OAT Ann Ala His 70 CAT CTG ATO His Lou Mat as AAA TTA MAT Lyn Lou Ann AT? TTG AA Ile Lou Lyn AGOC TT CAT CkG GAO TC TOO Bar Bar His Gin Asp Oar Bar
ACA
Thr
TTC
Pha 40
OCT
Ala
ATO
Mat Phe Ala
AAM
Lys 120 MAT GC Ann Ala CCT GAC Pro Asp 90 ATO TOT Ile Oar 105 TAT AGA Tyr Arg CMA AAA CAA 000 Gin Lyn Gin Ala OTG GSA TOG CAG Lou Gly Trp Gin TAT TOT GAT GOA Tyr Cyn Asp Gly ACC AC CAC OCT Thr Ann His Ala CAC OTA CCA AA His Val Pro Lyn OTT CTO TAO TTT Val Lou Tyr Pha 110 MAT ATO GTA OTA Ann Met Val Val 125
AGA
Arg
TOT
Cyn
GAO
Asp GAh Giu
ATA
Ile
CCT
Pro
OAT
Asp
COO
Arg
ATG
Mat
AAG
Lyn
TOO
Trp
TOT
Cys WO 95/160341 3PCTUS94/13181 INFORMATION FOR SOEQ ID NO-.s3 (W SEQUENCE CHARCTERISTIC1: LENGTH: 132 amino acids TYPE: amino acid TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO:t6: Ann Gln Ann Arg Ann Lyn Bar Sr Sor Bin l in Asp Bar Ser Arg Mt 1 S 10 1 Bar Bar Val Gly Anp Tyr Ann Thr Bar Giu Gin Lyn Gin Ala Cya Lyn 25 Lyn His Glu Lou Tyr Val 5cr Pho Arg Asp Lou Gly Trp Gin Asp Trp 40 Ilo Il Ala Pro Giu Gly Tyr Ala Ala Pho Tyr Cyn Asp Gly Glu Cyn s0 Ss Bar Phe Pro Lou Ann Ala His Met Ann Ala Thr Ann His Ala Ile Val 70 75 00 Gin Thr Lou Val Ilia Lou Mat Pho Pro Asp Hlin Val Pro Lyn Pro Cyn 90 Cyo Ala Pro Thr Lyn Lou Ann Ala Ile Bar Val Lou Tyr Phe AEp Asp 100 10S 110 Bar Bar AnR Val Ile Lou Lyn Lyn Tyr Arg Ann Mat Val Val Arg Bar 115 120 125 Cyn Giy Cys His 130 INFORMATION FOR SEQ ID NO:: SEQUENCE CHARACTERISTICS: LENGTH: 406 basn palr TYPE: nucloic acid STRANDrDtS8.- double TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (vi) ORIGINAL SOURCE: ORGAiNISM: bmp-9 (ix) FEATURE.: NAME/KEY: 0DS (11) LOCATION: 1..396 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:?: CAA CAG AGT CGT AAT WC TOT ACC CAG TCC CAG GAC GTO GCO GG 0 TC Gln Gln Bar Arg Ann Arg Bar Thr Gin Bar Gin Asp Val Ala Arg Val 1 5 10 1 7CC AGT GCT TCA CAT TAO AAC AGC AGT GAA 775 AAA ACA oCC T5 ASS 96 SOr Scr Ala ar Asp Tyr Ann Bar 13cr Glu Lou Lyn Thr Ala Cyd Arg 25 I _I WO 951160341 PCTIUS94/13181 AAG CAT GAG CTG TAT GT AGT TTC CAA GAC CTG GGA TOO CAG GAC TOO 144 Lyn His Glu LOU Tyr Val Bar Phe Gin Asp Lou Gly Trp Gin Aop Trp 40 ATC ATT GCA CCC AAG GGC TAT OCT GCC AAT TAC TOT GAT GGA GAM TGC 192 Ilo Ile Ala Pro Lyn Sly Tyr Ala Ala Ann Tyr Cya Aop Sly Glu Cy3 55 TCC TTC CCA CTC A7r.C GCA CAC ATG AAT GCA ACC AAC CAC GCG ATT GTG 240 Phe Pro Lou Ann Ala Hit) Met Ann Ala Thr Ann His Ala Ile Val 70 75 CAG ACC TTG OTT CAC CT? ATG AAC CCC GAG TAT GTC CCC AAA CCG TGC 288 Gin Thr Lou Val Hi Lou Met Ann Pro Glu Tyr Val Pro Lyn Pro Cyn 90 TOT GCG CCA ACT MAG CTA MAT 0CC ATC TCG OTT CT? TAC TTT GAT GAC 336 Cyn Ala Pro Thr Lyn Lou Ann Ala Ile Ber Val Lau Tyr Phe Asp Asp 100 105 110 MAC TCC MAT GTC AT? CTG AAA AAA TAC AGO MAT ATS GTT OTA AGA OCT 384 Ann Ser Ann Vol Ile Lau Lyn Lye Tyr Arg Ann Met Val Val Arg Ala 115 120 125 TOT GOA TGC CAC TAACTGAAA 406 Cyn ly Cyn Hig 130 INFORMATION FOR SEQ ID NO:8: SEQUENCE CHARACTERISTICS LENGTH. 132 amino acids TYPE: amino acid TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID N~tO: Gin Gin Bar Arg Ann Arg Bar Thr Gin Bar Gin Asp Vol Ala Arg Val 1 5 10 Bar Bar Ala Bar Asp Tyr Ann Bar Bar Olu Lou Lyn Thr Ala CyD Arg 25 Lye HN Glu Lou Tyr Vol Bar Phe Gin Asp Lou Gly Trp Gin Asp Trp 40 Ilo Ilo Ala Pro Lyn Sly Tyr Ala Ala Ann Tyr Cyn Asp Sly Glu Cys 55 Bar Pho Pro Lou Ann Ala Ilis Met Ann Ala Thr Ann His Ala le Val 70 75 0 Gin Tkr Lou Vol Hin Lou Mot Ann Pro Slu Tyr Vol Pro Lyn Pro Cyn 90 Cya Ala Pro Thr Lyn Lou Ann Ala Ile Bar Val Lou Tyr Pho Asp Asp 100 105 110 Ann Bar Ann Val le Lou Lyn Lyn Tyr Arg Ann Met Val Val Arg Ala 115 120 125 Cya Gly Cyn in 130
I^^
WO 95116034 WO 9516034PCTlUS94113181 INFORMATION FOR SEQ ID NO:qz Wi SEQUENCE CHARACTERISTICS: LENGTH: 417 bane pairs (BI TYPE: nucleic acid STRADEDNESS: double TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (vi) ORIGINAL SOURCE: ORGANISM: bmp-7 (ix) FEATURE: NAME/KEY: CDS LOCATION: 1. .417 (xi) SEQUENCE DESCRIPTION’ SEQ ID NO:,9t TCC ACG GGG AGC AAA CAG CGC AGC CAG AAC CGC TCC AAG ACG CCC MAG Ser Thr Gly Ser Lyn Gin Arg Ser Gin Ann
I
MAC CAG GMA Ann Gin Glu GAC CAG AGO Asp Gin Arg GAC CTG GCC Asp LOU Gly TAC TAO TGT Tyz. Tyr Cys 6s GCC ACC MAC Ala Thr Ann GMA ACC GTG Glu Thr Val TCC GTC CTC Ser Val Lau 115 AGA MAC ATO Arg Ann Met 130
CC
Ala 20
CAG
Gin
TGG
Trp
GAG
Giu,
CAC
His
CCC
Pro 100
TAC
Tyr
GTO
Val 5
CTG
Leu
CC
Ala
CAG
Gin
GG
Gly
GCC
Ala
MAG
Lyn
TTC
Phe
GTC
Val
CGG
Arg
TGT
CyD
GAC
Asp
GAG
Glu 70
ATC
Ile
CCC
pro
GAT
Asp
CGG
Azrg
ATO
Met
MAG
Lys
TGG
Trp 55
TGT
Cyn
GTG
Val
TGC
CyD
GAC
Asp
CC
Ala 135 10 GCC MAC GTG Ala Ann Val 25 MAG CAC GAG Lyn His Glu 40 ATC ATC GCG Ile Ile Ala GCC TTC CCT Ala Phe Pro CAG ACG CTG Gin Thr Lau 90 TGT GCG CCC Cya Ala Pro 105 AGC TCC MAC Ser Ser Ann 120 TGT GOC TOO Cys Gly Cys Arg
GCA
Ala
CTO
Lou
CCT
Pro
CTG
Lou .75
GTO
Val
ACG
Thr
GTC
Val
CAC
His Ser Lys GAG MAC Glu Ann TAT OTC Tyr Val GMA GCC Giu Gly so MAC TCC Ann Ser CAC TTC His Phe CAG CTC Gin LOU ATC CTG Ile Lou 125 Thr
AGC
Ser
AGO
Ser
TAC
Tyr?
TAO
Tyr
ATC
le
MAT
Ann 110
MAG
Lyn Pro Lys AGC AGO Ser Ser TTC COA Phe Arg GCC CC Ala Ala ATO MAC Met Ann s0 MAC CCG Ann Pro GCC ATO Ala Ile AMA TAC Lys Tyr 96 144 192 240 288 336 384 INFORMATION FOPR SEQ ID SEQUENCE CHARACTERISTICS: LENGTH- 139 amino acids TYPE:- amino acid TOPOLOGY-. linear (ii) MOLECULE TYPE: protein WO 95116034 PCT/IUS94/3181 (xi) SEQUENCE DESCRIPTION: SEQ ID Ser Thr Gly Ser Lyo Gln Arg Ser Gin Ann Arg Ser Ly Thr Pro Lyn 1 5 10 Ann Gln Glu Ala Leu Arg Met Ala Ann Val Ala Glu Ann Ser Ser Set 25 Asp Gin Arg Gin Ala Cys Lys Lys His Glu Leu Tyr Val Ser Phe Arg 40 Asp Leu Gly Trp Gin Asp Trp Ile Ile Ala Pro Glu Gly Tyr Ala Ala 55 Tyr Tyr Cys Glu Gly Glu Cys Ala Phe Pro Leu Ann Ser Tyr Met Asn 70 75 Ala Thr Ann His Ala Ile Val %In Thr Leu Val His Phe Ile Ann Pro 90 Glu Thr Val Pro Lyn Pro Cyn Cyn Ala Pro Thr Gln Leu Ann Ala Ile 100 105 110 Ser Val Leu Tyr Phe Asp Asp Ser Ser Ann Val Ile Leu Lyn Lys Tyr 115 120 125 Arg Ann Met Val Val Arg Ala Cys Gly Cys His 130 135 INFORMATION FOR SEQ ID NO:ii: SEQUENCE CHARACTERISTICS: LENGTH: 420 base pairs TYPE: nucleic acid STRANDEDNESS: double TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (vi) ORIGINAL SOURCE: STRAIN: BMP-8 (ix) FEATURE: NAME/KEY: CDS LOCATION: 1..417 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:11: GCA GTG AGG CCA CTG AGG AGGO AGGO CAG CCG AAG AAA AGC AAC GAG CTG 48 Ala Val Arg Pro Leu Arg Arg Arg Gln Pro Lys Lys Ser Asn Glu Leu 1 5 10 CCG CAG GCC AAC CGA CTC CCA GGG ATC TTT GAT GAC GTC CAC GGC TCC 96 Pro Gin Ala Ann Arg Leu Pro Gly lle Phe Asp Asp Val His Gly Ser 25 CAC GGC CGG CAG GTC TGC CGT CGG CAC GAG CTC TAC GTC AGC TTC CAG 144 His Gly Arg Gln Val Cys Arg Arg His Glu Leu Tyr Val Ser Phe Gln 40 GAC CTT GGC TGG CTG GAC TGG GTC ATC GCC CC CAA GGC TAC TCA GCC 192 Asp Leu Gly Trp Leu Asp Trp Val Ile Ala Pro Gin Gly Tyr Ser Ala 55 TAT TAC TGT GAG GGG GAG TGC TCC TTC CCG CTG GAC TCC TGC ATG AAC 240 31 WO 95116034l PCTIUS9413181 Tyr Tyr Cys Glu Gly Gu Cyo Ser Phe Pro Lou 70 GCC ACC AAC CAC GCC ATC CTG CAG TCC CTG GTG Ala Thr Ann His Ala Ile Lou Gln Ser LaU Val 90 AAC GCA GTC CCC AAG GC TGC TOT OCA CCC ACC Asn Ala Val Pro Lyn Ala Cys Cys Ala Pro Thr 100 105 TCT GTG CTC TAC TAT GAC AGC AGC AAC AAC GTC Ser Val Lau Tyr Tyr Asp Ser Ser Ann Asn Val 115 120 CGC AAC ATG GTG GTC AAG GCC TGC GGC TGC CAC Arg Asn Met Val Val Lys Ala Cyn Gly Cy8 His 130 135 INFORMATION FOR SEQ ID NO:12: SEQUENCE CHARACTERISTICS: LENGTH: 139 amino acids TYPE: amino acid TOPOLOGY: linear Asp Ser Cyn Met CAC CTG ATG AAG His Lou Met Lys AAG CTG AGC OCC LyS Lou Ser Ala 110 ATC CTG CGC MAG Ile Leu Arg Lys 125
TGA
(ii) MOLECULE TYPE: protein Ala 1 Pro His Asp Tyr Ala Asn Ser Arg (xi) SEQUENCE Val Arg Pro Lou 5 Gin Ala Asn Ag Gly Arg Gin Val Lou Gly Trp Leu Tyr Cys Glu Gly Thr Ann His Ala 8 Ala Val Dro Lys 11)0 Val Lou Tyr Tyr Asn Met Val Val 130 DESCRIPTION: SEQ ID Arg Arg Arg Gin Pro 10 Lou Pro Gly Ile Phe Cys Arg Arg His Glu 40 Asp Trp Val Ile Ala 55 Glu Cys Ser Phe Pro 70 Ile Lou Gin Sor Lou 90 Ala Cys Cys Ala Pro 105 Asp Ser Ser Asn Asn 120 Lys Ala Cys Gly Cys 135 NO;.12: Lys Lys Asp Asp Lou Tyr Pro Gln Lou Asp 75 Val His Thr LS Val Ile His Ser Val Val Gly Ser Lou Lou Lou 125 Glu Gly Phe Ser Met Lys Ala Lys Lou Ser Gin Ala Ann Pro Thr His
I

Claims (14)

1. A recombinant DNA molecule comprising a nucleotide sequence encoding BMP-4 as shown in SEQ ID NO:3, except that the nucleotide triplet at 319 to 321 has been replaced with a triplet encoding aspartic acid.

2. A recombinant DNA molecule comprising a nucleotide sequence encoding as shown in SEQ ID NO:5, except that the nucleotide triplet at 166 to 168 has been replaced with a triplet encoding histidine.

3. A recombinant DNA molecule comprising a nucleotide sequence encoding BMP-6 as shown in SEQ ID NO:7, except that the nucleotide triplet at 166 to 168 has been replaced with a triplet encoding histidine.

4. A recombinant DNA molecule comprising a nucleotide sequence encoding BMP-7 as shown in SEQ ID NO:9, except that the nucleotide triplet at 187 to 189 has been replaced with a triplet encoding histidine. A recombinant DNA molecule comprising a nucleotide sequence encoding BMP-8 as shown in SEQ ID NO:11, except that the nucleotide triplet at 187 to 189 has been replaced with a triplet encoding histidine.

6. A purified composition of a mutant BMP-4 comprising the amino acid sequence of SEQ ID NO:4, wherein the glutamic acid at amino acid residue 107 has been replaced with aspartic acid.

7. A purified composition of a mutant BMP-5 comprising the amino acid sequence of SEQ ID NO:6, wherein the alanine at amino acid residue 56 has been replaced with histidine.

8. A purified composition of a mutant BMP-6 comprising the amino acid sequence of SEQ ID NO:8, wherein the alanine at amino ac -esidue 56 has been replaced with histidine.

9. A purified composition of a mutant BMP-7 comprising the amino acid sequence of SEQ ID NO:10, wherein the alanine at amino acid residue 63 has been replaced with histidine. A purified composition of a mutant BMP-8 comprising the amino acid sequence of SEQ ID NO:12, wherein the serine at amino acid residue 63 has been replaced with histidine. I WO 95/16034 PCT/US94/13181

11. A purified composition of BMP heterodimer comprising at least one mutant BMP according to claim 6.

12. A purified composition mutant BMP according to claim 7.

13. A purified composition mutant BMP according to claim 8.

14. A purified composition mutant BMP according to claim 9. A purified composition mutant BMP according to claim of BMP heterodimer comprising at least one of BMP heterodimer comprising at least one of BMP heterodimer comprising at least one of BMP heterodimer comprising at least one

16. A method of obtaining mutants of bone morphogenetic proteins (BMP) with improved refolding properties, said method comprising: a) comparing the amino acid sequence of a BMP which is found to refold well (BMP+) with the amino acid sequence of a BMP which does not refold well (BMP-); b) determining the differences at correlative amino acid positions in the comparison of step c) altering the amino acid sequence of BMP- so that one amino acid which is different from that of the correlative amino acid of BMP+ is replaced by the correlative amino acid of BMP+ to form a modified BMP- protein; d) testing the modified BMP- protein for its ability to refold.

17. A mutant of bone morphogenetic proteins (BMP) with improved refolding properties produced by the method of claim 16. I

AU12093/95A
1993-12-07
1994-11-15
Mutants of bone morphogenetic proteins

Ceased

AU682238B2
(en)

Applications Claiming Priority (3)

Application Number
Priority Date
Filing Date
Title

US163877

1993-12-07

US08/163,877

US5399677A
(en)

1993-12-07
1993-12-07
Mutants of bone morphogenetic proteins

PCT/US1994/013181

WO1995016034A1
(en)

1993-12-07
1994-11-15
Mutants of bone morphogenetic proteins

Publications (2)

Publication Number
Publication Date

AU1209395A

AU1209395A
(en)

1995-06-27

AU682238B2
true

AU682238B2
(en)

1997-09-25

Family
ID=22591964
Family Applications (1)

Application Number
Title
Priority Date
Filing Date

AU12093/95A
Ceased

AU682238B2
(en)

1993-12-07
1994-11-15
Mutants of bone morphogenetic proteins

Country Status (16)

Country
Link

US
(3)

US5399677A
(en)

EP
(1)

EP0733108B1
(en)

JP
(1)

JP3704350B2
(en)

KR
(1)

KR100361058B1
(en)

AT
(1)

ATE200515T1
(en)

AU
(1)

AU682238B2
(en)

CA
(1)

CA2176943C
(en)

DE
(1)

DE69427093T2
(en)

DK
(1)

DK0733108T3
(en)

ES
(1)

ES2157313T3
(en)

FI
(1)

FI118428B
(en)

GR
(1)

GR3035769T3
(en)

NO
(1)

NO317800B1
(en)

OA
(1)

OA10294A
(en)

PT
(1)

PT733108E
(en)

WO
(1)

WO1995016034A1
(en)

Families Citing this family (70)

* Cited by examiner, † Cited by third party

Publication number
Priority date
Publication date
Assignee
Title

US6150328A
(en)

*

1986-07-01
2000-11-21
Genetics Institute, Inc.
BMP products

US20080139474A1
(en)

*

1991-11-04
2008-06-12
David Israel
Recombinant bone morphogenetic protein heterodimers, compositions and methods of use

DE69233022T2
(en)

1991-11-04
2004-02-12
Genetics Institute, LLC, Cambridge

RECOMBINANT BONE MORPHOGENETIC PROTEIN HETERODIMERS, COMPOSITIONS AND METHODS OF USE

US6291206B1
(en)

*

1993-09-17
2001-09-18
Genetics Institute, Inc.
BMP receptor proteins

ATE319823T1
(en)

*

1993-12-07
2006-03-15
Inst Genetics Llc

BMP-12, BMP-13 AND TENDON-INDUCING COMPOSITIONS CONTAINING SAME

US5942496A
(en)

1994-02-18
1999-08-24
The Regent Of The University Of Michigan
Methods and compositions for multiple gene transfer into bone cells

US6551618B2
(en)

1994-03-15
2003-04-22
University Of Birmingham
Compositions and methods for delivery of agents for neuronal regeneration and survival

NZ305472A
(en)

1995-04-19
1999-09-29
Hoechst Marion Roussel Ltd For
A protein derived from human mp52 useful in treating cartilage and bone diseases

US6040431A
(en)

*

1995-06-07
2000-03-21
Stryker Corporation
Single chain analogs of the TGF-β superfamily (morphons)

US7026292B1
(en)

1995-12-12
2006-04-11
Stryker Corporation
Compositions and therapeutic methods using morphogenic proteins and stimulatory factors

US6048964A
(en)

*

1995-12-12
2000-04-11
Stryker Corporation
Compositions and therapeutic methods using morphogenic proteins and stimulatory factors

US5869041A
(en)

*

1996-01-12
1999-02-09
The Miriam Hospital
Delivery of bioactive compounds to an organism

ZA9711580B
(en)

*

1996-12-25
1999-09-23
Hoechst Marion Roussel Ltd
Process for the production of purified dimeric bone morphogenetic factors.

US20040019185A1
(en)

*

1996-12-25
2004-01-29
Hidetoshi Andou
Process for preparing purified active monomer of bone-derived factor

US7811793B2
(en)

*

1996-12-25
2010-10-12
Biopharma Gesellschaft Zur Biotechnologischen Entwicklung Von Pharmaka Mbh
Process for preparing purified active monomer of bone-derived factor

US20020052026A1
(en)

*

1997-10-08
2002-05-02
Steven M. Vicik
Methods of refolding proteins

US6391311B1
(en)

1998-03-17
2002-05-21
Genentech, Inc.
Polypeptides having homology to vascular endothelial cell growth factor and bone morphogenetic protein 1

EP2050762A3
(en)

1998-03-10
2009-07-08
Genentech, Inc.
Human cornichon-like protein and nucleic acids encoding it

PT2016951E
(en)

1998-03-17
2012-09-27
Genentech Inc
Polypeptides homologous to vegf and bmp1

US6677432B1
(en)

*

1998-10-07
2004-01-13
Stryker Corporation
Mutations of the C-terminal portion of TGF-β superfamily proteins

JP3762222B2
(en)

*

1998-10-07
2006-04-05
ストライカー・コーポレーション

Modified TGF-β superfamily protein

US6846906B1
(en)

1998-10-07
2005-01-25
Stryker Corporation
Modified proteins of the TGF-β superfamily, including morphogenic proteins

US6727224B1
(en)

*

1999-02-01
2004-04-27
Genetics Institute, Llc.
Methods and compositions for healing and repair of articular cartilage

DE19906096A1
(en)

1999-02-13
2000-08-17
Walter Sebald

Protein with a heparin-binding epitope

DE19944626A1
(en)

*

1999-09-17
2001-03-22
Knoell Hans Forschung Ev
Producing active bone morphogenic protein dimers, useful for inducing growth of bone and cartilage comprises expressing soluble fusion protein monomer followed by refolding and dimerization

PT1223990E
(en)

1999-10-15
2004-12-31
Fidia Advanced Biopolymers Srl

HYALURONIC ACID FORMULATIONS FOR ADMINISTRATION OF OSTEOGENIC PROTEINS

US7740841B1
(en)

2000-01-28
2010-06-22
Sunnybrook Health Science Center
Therapeutic method for reducing angiogenesis

US20030104977A1
(en)

*

2000-03-31
2003-06-05
Ugo Ripamonti
Methods for inducing angiogenesis using morphogenic proteins and stimulatory factors

DE10026713A1
(en)

*

2000-05-30
2001-12-06
Walter Sebald

Mutein a chain of a protein from the superfamily of the growth factor TGF-beta

US20030082233A1
(en)

*

2000-12-01
2003-05-01
Lyons Karen M.
Method and composition for modulating bone growth

JP2005500280A
(en)

*

2001-06-01
2005-01-06
ワイエス

Compositions and methods for systemic administration of sequences encoding bone morphogenetic proteins (BMPs)

TWI267378B
(en)

*

2001-06-08
2006-12-01
Wyeth Corp
Calcium phosphate delivery vehicles for osteoinductive proteins

FI117667B
(en)

*

2001-07-05
2007-01-15
Univ Zuerich

A pharmaceutical composition suitable for use in orthopedics and dentistry

JP4879482B2
(en)

*

2002-05-17
2012-02-22
ワイス・エルエルシー

Injectable solid hyaluronic acid carrier for delivering osteogenic proteins

US20040023322A1
(en)

*

2002-08-01
2004-02-05
Goodheart Clyde R.
Method of producing non-recombinant BMP-2 and use thereof

CA2531969C
(en)

*

2003-07-09
2011-04-26
National Institute Of Advanced Industrial Science And Technology
Protein-refolding material

KR20060133961A
(en)

*

2003-09-12
2006-12-27
와이어쓰
Injectable calcium phosphate solid rods and pastes for delivery of osteogenic proteins

US7576052B2
(en)

2003-10-17
2009-08-18
Joslin Diabetes Center, Inc.
Methods and compositions for modulating adipocyte function

US20070066525A1
(en)

*

2004-02-04
2007-03-22
Lee John C
Compositions and therapeutic methods using morphogenic proteins

AU2005244942A1
(en)

*

2004-05-19
2005-12-01
Wyeth
Modulation of immunoglobulin production and atopic disorders

US20060039902A1
(en)

*

2004-08-05
2006-02-23
Young Deborah A
Antagonizing interleukin-21 receptor activity

KR20070107703A
(en)

2005-02-14
2007-11-07
와이어쓰
Interleukin-17f antibodies and other il-17f signaling antagonists and uses therefor

JP2008532493A
(en)

*

2005-02-14
2008-08-21
ワイス

Characterization of the interaction between IL-17F and IL-17R

WO2006105359A2
(en)

*

2005-03-30
2006-10-05
Wyeth
Methods for stimulating hair growth by administering bmps

GT200600148A
(en)

2005-04-14
2006-11-22

METHODS FOR THE TREATMENT AND PREVENTION OF FIBROSIS

EP1885750B1
(en)

2005-05-27
2011-08-17
BBS – Bioactive Bone Substitutes Oy
Bone morphogenetic protein 4 and osteogenic devices and pharmaceutical products containing thereof

US7851435B2
(en)

2005-05-27
2010-12-14
Bbs-Bioactive Bone Substitutes Oy
Bone morphogenetic protein 3 and osteogenic devices and pharmaceutical products containing thereof

EP1885751B1
(en)

2005-05-27
2011-11-16
BBS – Bioactive Bone Substitutes Oy
Bone morphogenetic protein 6 containing a heparin binding site and osteogenic devices and pharmaceutical products containing thereof

US20100150885A1
(en)

2005-06-01
2010-06-17
Joslin Diabetes Center, Inc.
Methods and compositions for inducing brown adipogenesis

GB0604964D0
(en)

*

2006-03-11
2006-04-19
Renovo Ltd
Protein folding

GB0604966D0
(en)

2006-03-11
2006-04-19
Renovo Ltd
Medicaments and proteins

GB0604938D0
(en)

2006-03-11
2006-04-19
Renovo Ltd
Proteins, nucleic acids and medicaments

EP2024495A2
(en)

*

2006-05-25
2009-02-18
Wyeth
Expression of the cysteine protease legumain in vascular and inflammatory diseases

CN104152395B
(en)

*

2006-11-08
2020-03-10
惠氏公司
Rationally designed cell culture media

AU2007339280B2
(en)

2006-12-21
2013-12-05
Stryker Corporation
Sustained-release formulations comprising crystals, macromolecular gels, and particulate suspensions of biologic agents

CL2008000883A1
(en)

*

2007-03-28
2008-10-03
Wyeth6 3

METHOD OF DETECTION OF CAPABLE COMPOUNDS TO ANTAGONIZE THE SIGNALING OF IL-17F / IL-17A; COMPOUND IDENTIFIED BY SUCH METHOD; USE OF A QUANTITY OF AN IL-17F / IL-17A SENALIZATION ANTAGONIST, PHARMACEUTICAL COMPOSITION UNDERSTANDING

TW200902708A
(en)

*

2007-04-23
2009-01-16
Wyeth Corp
Methods of protein production using anti-senescence compounds

EP2019117A1
(en)

*

2007-07-27
2009-01-28
BIOPHARM GESELLSCHAFT ZUR BIOTECHNOLOGISCHEN ENTWICKLUNG VON PHARMAKA mbH
Optimized purification process of recombinant growth factor protein

WO2009023562A2
(en)

2007-08-09
2009-02-19
Wyeth
Use of perfusion to enhance production of fed-batch cell culture in bioreactors

US8058407B2
(en)

*

2008-10-31
2011-11-15
Wyeth Llc
Purification of acidic proteins using ceramic hydroxyapatite chromatography

AU2010213591B2
(en)

2009-02-12
2013-11-21
Stryker Corporation
Compositions and methods for minimally-invasive systemic delivery of proteins including TGF-beta superfamily members

AU2010213575B2
(en)

2009-02-12
2013-11-14
Stryker Corporation
Peripheral administration of proteins including TGF-beta superfamily members for systemic treatment of disorders and disease

WO2010110974A1
(en)

2009-03-24
2010-09-30
Stryker Corporation
Methods and compositions for tissue engineering

WO2011031856A1
(en)

2009-09-09
2011-03-17
Stryker Corporation
Bmp -7 for use in treating pain induced by injuries and diseases of an articular joint

WO2011035094A1
(en)

2009-09-17
2011-03-24
Stryker Corporation
Buffers for controlling the ph of bone morphogenetic proteins

CN102822197A
(en)

2009-12-22
2012-12-12
史赛克公司
BMP-7 variants with reduced immunogenicity

US20190135884A1
(en)

*

2016-05-31
2019-05-09
Mogam Institute For Biomedical Research
Composition comprising an ab6 family designer ligand of tgf-beta superfamily for treating bone and cartilage disease and use thereof

KR20190005239A
(en)

*

2016-05-31
2019-01-15
재단법인 목암생명과학연구소

Composition for the treatment of liver disease, including the AB6 family designer ligand of the TGF-beta super family and use thereof

WO2017209519A1
(en)

*

2016-05-31
2017-12-07
Mogam Institute For Biomedical Research
Ab6 family designer ligands of tgf-beta superfamily

CN115335393A
(en)

*

2020-03-24
2022-11-11
博奥泰克尼公司
Methods of using TGF-beta knockout cell lines and compositions produced therefrom

Family Cites Families (10)

* Cited by examiner, † Cited by third party

Publication number
Priority date
Publication date
Assignee
Title

GR79124B
(en)

*

1982-12-22
1984-10-02
Genentech Inc

US5187076A
(en)

*

1986-07-01
1993-02-16
Genetics Institute, Inc.
DNA sequences encoding BMP-6 proteins

US5106748A
(en)

*

1986-07-01
1992-04-21
Genetics Institute, Inc.
Dna sequences encoding 5 proteins

US5013649A
(en)

*

1986-07-01
1991-05-07
Genetics Institute, Inc.
DNA sequences encoding osteoinductive products

ZA874681B
(en)

*

1986-07-01
1988-04-27
Genetics Inst
Novel osteoinductive factors

GB8927546D0
(en)

*

1989-12-06
1990-02-07
Ciba Geigy
Process for the production of biologically active tgf-beta

JPH06500991A
(en)

*

1990-05-16
1994-01-27
ジェネティックス・インスティテュート・インコーポレイテッド

Bone and cartilage-inducing protein

ES2161693T3
(en)

*

1991-03-11
2001-12-16
Curis Inc

MORPHOGENESIS INDUCED BY PROTEINS.

ES2127757T3
(en)

*

1991-06-25
1999-05-01
Genetics Inst

COMPOSITIONS BMP-9.

DE69233022T2
(en)

*

1991-11-04
2004-02-12
Genetics Institute, LLC, Cambridge

RECOMBINANT BONE MORPHOGENETIC PROTEIN HETERODIMERS, COMPOSITIONS AND METHODS OF USE

1993

1993-12-07
US
US08/163,877
patent/US5399677A/en
not_active
Expired – Lifetime

1994

1994-11-15
DE
DE69427093T
patent/DE69427093T2/en
not_active
Expired – Lifetime

1994-11-15
AT
AT95903116T
patent/ATE200515T1/en
not_active
IP Right Cessation

1994-11-15
EP
EP95903116A
patent/EP0733108B1/en
not_active
Expired – Lifetime

1994-11-15
CA
CA002176943A
patent/CA2176943C/en
not_active
Expired – Lifetime

1994-11-15
ES
ES95903116T
patent/ES2157313T3/en
not_active
Expired – Lifetime

1994-11-15
KR
KR1019960703011A
patent/KR100361058B1/en
not_active
IP Right Cessation

1994-11-15
WO
PCT/US1994/013181
patent/WO1995016034A1/en
active
IP Right Grant

1994-11-15
DK
DK95903116T
patent/DK0733108T3/en
active

1994-11-15
AU
AU12093/95A
patent/AU682238B2/en
not_active
Ceased

1994-11-15
PT
PT95903116T
patent/PT733108E/en
unknown

1994-11-15
JP
JP51619695A
patent/JP3704350B2/en
not_active
Expired – Fee Related

1994-12-21
US
US08/360,914
patent/US5756308A/en
not_active
Expired – Lifetime

1996

1996-06-04
NO
NO19962303A
patent/NO317800B1/en
unknown

1996-06-06
FI
FI962349A
patent/FI118428B/en
active
IP Right Grant

1996-06-07
OA
OA60839A
patent/OA10294A/en
unknown

1996-10-31
US
US08/741,589
patent/US5804416A/en
not_active
Expired – Lifetime

2001

2001-04-20
GR
GR20010400618T
patent/GR3035769T3/en
not_active
IP Right Cessation

Also Published As

Publication number
Publication date

KR960706558A
(en)

1996-12-09

GR3035769T3
(en)

2001-07-31

DE69427093D1
(en)

2001-05-17

NO962303L
(en)

1996-06-04

ATE200515T1
(en)

2001-04-15

DK0733108T3
(en)

2001-06-18

WO1995016034A1
(en)

1995-06-15

FI962349A0
(en)

1996-06-06

US5756308A
(en)

1998-05-26

NO317800B1
(en)

2004-12-13

CA2176943C
(en)

2007-04-03

JPH09506259A
(en)

1997-06-24

FI118428B
(en)

2007-11-15

AU1209395A
(en)

1995-06-27

JP3704350B2
(en)

2005-10-12

FI962349A
(en)

1996-07-16

US5804416A
(en)

1998-09-08

KR100361058B1
(en)

2003-04-10

DE69427093T2
(en)

2001-11-15

NO962303D0
(en)

1996-06-04

PT733108E
(en)

2001-08-30

US5399677A
(en)

1995-03-21

EP0733108A1
(en)

1996-09-25

ES2157313T3
(en)

2001-08-16

OA10294A
(en)

1997-10-07

EP0733108B1
(en)

2001-04-11

CA2176943A1
(en)

1995-06-15

Similar Documents

Publication
Publication Date
Title

AU682238B2
(en)

1997-09-25

Mutants of bone morphogenetic proteins

AU677849B2
(en)

1997-05-08

BMP-10 compositions

CA2656835C
(en)

2017-12-19

Refolding of recombinant proteins

US6593106B1
(en)

2003-07-15

Methods of refolding proteins

CA2161808C
(en)

2008-08-05

Bmp-11 compositions

CA2176942C
(en)

2011-11-01

Bmp-12, bmp-13 and tendon-inducing compositions thereof

EP1690874B1
(en)

2011-05-25

BMP-12, BMP-13 and tendon-inducing compositions thereof

CA2313381A1
(en)

1999-06-17

Bone morphogenetic protein (bmp)-17 and bmp-18 and compositions thereof

JP4272357B2
(en)

2009-06-03

Novel monomeric proteins with osteoinductive activity and preventive and therapeutic agents for bone / cartilage diseases comprising them

US5830761A
(en)

1998-11-03

Medium and methods for culturing mammalian cho cells

AU6870791A
(en)

1991-05-16

Biosynthetic constructs of tgf-beta

CA2574929C
(en)

2011-08-23

Bone morphogenetic protein (bmp)-17 and bmp-18 and compositions

EP2912173B1
(en)

2019-11-13

Process for preparation and purification of recombinant human oncostatin m protein

MXPA00003436A
(en)

2001-05-07

Methods of refolding proteins by use of zwitterionic low molecular weight agents

JPH09262093A
(en)

1997-10-07

Activation of protein

Legal Events

Date
Code
Title
Description

2003-02-06
HB
Alteration of name in register

Owner name:
GENETICS INSTITUTE, LLC

Free format text:
FORMER NAME WAS: GENETICS INSTITUTE, INC.

Download PDF in English